High-content adhesion assay to address limited cell samples.

Current cell adhesion methods fail when working with limited cell samples. Traditional assays require large cell numbers, making them unsuitable for small biopsies or rare cell isolates. Prior research has shown that adhesion is critical in cancer progression and tissue development. However, no prior work had resolved how to study adhesion with fewer than 10^5 cells. This gap motivated the development of a new platform. The need to analyze small cell populations is especially relevant in clinical and rare cell research settings. No existing tools could quantify adhesion at the 10^2 to 10^3 cell level. This limitation hindered progress in areas like regenerative medicine and cancer metastasis. The new approach aims to fill this gap by enabling high-content adhesion analysis with minimal cell input.

The study aimed to develop an adhesion assay suitable for limited cell numbers. The goal was to quantify adhesion using only 10^2 to 10^3 cells at a time. This approach addresses a key limitation in current methods. The researchers focused on engineered substrates to enable precise measurements. They also sought to capture population heterogeneity in adhesion. The platform needed to be validated across multiple cell types and conditions. The study aimed to demonstrate its utility in translational research settings. The ultimate goal was to enable new biological studies with rare or limited cell samples.

The team created engineered substrates to study cell adhesion. They used distribution-based modeling to assess adhesion strength and heterogeneity. The assay was tested with cancer cells from breast, prostate, and multiple myeloma. Endothelial monolayers were used in both activated and non-activated states. The platform quantified adhesion at the single-cell and population levels. Primary bone marrow stromal cells were used to test the assay’s versatility. Cardiac fibroblast-derived matrices served as substrates for adhesion analysis. The method enabled high-content data extraction from small cell populations.

The assay successfully quantified adhesion with as few as 10^2 to 10^3 cells. Cancer cells showed increased adhesion on activated endothelial monolayers. Each cancer type exhibited distinct adhesion patterns upon activation. The method identified and quantified subpopulations of cell-substrate interactions. Bone marrow stromal cells adhered differently to cardiac fibroblast matrices. The assay captured population heterogeneity in adhesion strength. Results demonstrated the platform’s sensitivity and robustness. The findings suggest the assay is suitable for limited and rare cell samples.

The new assay enables adhesion studies with limited cell numbers. It supports high-content analysis of adhesion strength and heterogeneity. The platform was validated across multiple cancer types and substrates. The method detected distinct subpopulations of cell-substrate interactions. Bone marrow stromal cell adhesion was successfully characterized. The assay’s sensitivity and robustness were confirmed through multiple experiments. The platform is suitable for translational research with rare cell samples. The authors propose this method will enable new biological studies in basic and translational research.